Industry Update: Interim 503A and 503B Bulks Lists New Revisions PEPTIDES: THE 2026 FDA CRACKDOWN CONTROVERSYWhy this is MASSIVE SEO RIGHT NOW BPC 157 banned The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law